探讨CLU调控Tau病理参与阿尔茨海默病的发病机制
Exploring the Mechanism of CLU Regulating Tau Pathology in the Pathogenesis of Alzheimer’s Disease
DOI: 10.12677/acm.2024.1451464, PDF,    科研立项经费支持
作者: 周 杰, 朱建英, 马雅茹:宁夏医科大学临床医学院,宁夏 银川;杨 平*:宁夏医科大学总医院神经内科,宁夏 银川
关键词: CLUTau蛋白阿尔茨海默病发病机制CLU Tau Protein Alzheimer’s Disease Pathogenesis
摘要: 目的:探讨CLU调控Tau进而参与阿尔茨海默病的可能发病机制。方法:1) 通过慢病毒转染人源性SH-SY5Y神经细胞构建CLU表达水平细胞模型,利用RT-qPCR、Western-blotting等方法检验细胞模型中CLU及Tau蛋白表达量。2) 利用QPCR技术在转录水平验证CLU的干扰和过表达,以及CLU干扰和过表达后对Tau的影响。结果:1) 利用CLU质粒转染至SH-SY5Y细胞中及正常SH-SY5Y细胞的cDNA为模板,通过RT-qPCR检测Tau在CLU过表达模型细胞中表达量明显高于正常组。2) 发现CLU的过表达同时会引起Tau表达量的增高,而CLU的干扰同时会引起Tau表达量的降低。结论:通过CLU质粒转染及过表达,调控Tau蛋白播散参与,从而引起阿尔茨海默病的发生。
Abstract: Objective: To explore the possible mechanism by which CLU regulates Tau and participates in the pathogenesis of Alzheimer’s disease. Method: 1) A CLU expression level cell model was constructed by transfecting human SH-SY5Y neural cells with lentivirus, and the expression levels of CLU and Tau proteins in the cell model were tested using RT qPCR, Western blotting, and other methods. 2) Using QPCR technology to verify the interference and overexpression of CLU at the transcriptional level, as well as the impact of CLU interference and overexpression on Tau. Result: 1) Using CLU plasmid transfection into SH-SY5Y cells and cDNA from normal SH-SY5Y cells as templates, the expression level of Tau in CLU overexpression model cells was significantly higher than that in the normal group detected by RT qPCR. 2) It was found that overexpression of CLU can also cause an increase in Tau expression, while interference from CLU can also lead to a decrease in Tau expression. Conclusion: By transfecting and overexpressing the CLU plasmid, the diffusion of Tau protein is regulated, leading to the occurrence of Alzheimer’s disease.
文章引用:周杰, 朱建英, 马雅茹, 杨平. 探讨CLU调控Tau病理参与阿尔茨海默病的发病机制[J]. 临床医学进展, 2024, 14(5): 567-575. https://doi.org/10.12677/acm.2024.1451464

参考文献

[1] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C.E., Cummings, J. and Van Der Flier, W.M. (2021) Alzheimer’s Disease. Lancet, 397, 1577-1590. [Google Scholar] [CrossRef
[2] Braak, H. and Braak, E. (1991) Neuropathological Stageing of Alzheimer-Related Changes. Acta Neuropathologica, 82, 239-259. [Google Scholar] [CrossRef
[3] Corneveaux, J.J., Myers, A.J., Allen, A.N., Pruzin, J.J. and Ramirez, M. (2010) Association of CR1, CLU and PICALM with Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals. Human Molecular Genetics, 19, 3295-3301. [Google Scholar] [CrossRef] [PubMed]
[4] De Silva, H.V., Harmony, J.A., Stuart, W.D., Gil, C.M. and Robbins, J. (1990) Apolipoprotein J: Structure and Tissue Distribution. Biochemistry, 5, 5380-5389 [Google Scholar] [CrossRef] [PubMed]
[5] Trougakos, I.P. and Gonos, E.S. (2002) Clusterin/Apolipoprotein J in Human Aging and Cancer. The International Journal of Biochemistry & Cell Biology, 34, 1430-1448. [Google Scholar] [CrossRef
[6] DeMattos, R.B., Cirrito, J.R., Parsadanian, M., May, P.C. and O’Dell, M.A. (2004) ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition: Evidence That ApE Regulates Extracellular Aβ Metabolism in Vivo. Neuron, 41, 193-202. [Google Scholar] [CrossRef
[7] Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H. and DeMattos, R.B. (2011) Human ApoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance. Science Translational Medicine, 3, 89ra57. [Google Scholar] [CrossRef] [PubMed]
[8] Kang, S.W., Shin, Y.J., Shim, Y.J., Jeong, S.Y. and Park, I.S. (2005) Clusterin Interacts with SCLIP (SCG10-Like Protein) and Promotes Neurite Outgrowth of PC12 Cells. Experimental Cell Research, 309, 305-315. [Google Scholar] [CrossRef] [PubMed]
[9] May, P.C., Lampert-Etchells, M., Johnson, S.A., Poirier, J. and Masters, J.N. (1990) Dynamics of Gene Expression for a Hippocampal Glycoprotein Elevated in Alzheimer’s Disease and in Response to Experimental Lesions in Rat. Neuron, 5, 831-839. [Google Scholar] [CrossRef
[10] Schrijvers, E.M., Koudstaal, P.J., Hofman, A. and Breteler, M.M. (2011) Plasma Clusterin and the Risk of Alzheimer Disease. JAMA: The Journal of the American Medical Association, 305, 1322-1326. [Google Scholar] [CrossRef] [PubMed]
[11] Yan, D., Yao, J., Liu, Y., et al. (2018) Tau Hyperphosphorylation and P-CREB Reduction Areinvolved in Acrylamide-Induced Spatial Memory Impairment: Suppression by Curcumin. Brain, Behavior, and Immunity, 71, 66-80. [Google Scholar] [CrossRef] [PubMed]
[12] Fernández-Nogales, M., Cabrera, J.R., Santos-Galindo, M., et al. (2014) Huntington’s Disease Is a Four-Repeat Tauopathy with Tau Nuclear Rods. Nature Medicine, 20, 881-885. [Google Scholar] [CrossRef] [PubMed]
[13] Stepan, J., Dine, J. and Eder, M. (2015) Functional Optical Probing of the Hippocampal Trisynaptic Circuit in Vitro: Network Dynamics, Filter Properties, and Polysynaptic Induction of CA1 LTP. Frontiers in Neuroscience, 9, Article 160. [Google Scholar] [CrossRef] [PubMed]
[14] Garey, J. and Paule, M.G. (2010) Effects of Chronic Oral Acrylamide Exposure on Incremental Repeated Acquisition (Learning) Task Performance in Fischer 34rats. Neurotoxicology and Teratology, 32, 220-225. [Google Scholar] [CrossRef] [PubMed]
[15] Augustinack, J.C., Schneider, A., Mandelkow, E.M., et al. (2002) Specific Tau Phosphorylation Sites Correlate with Severity of Neuronal Cytopathology in Alzheimer’s Disease. Acta Neuropathologica, 103, 26-35. [Google Scholar] [CrossRef] [PubMed]
[16] Serrano-Pozo, A., Frosch, M.P., Masliah, E., et al. (2011) Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 1, A006189. [Google Scholar] [CrossRef] [PubMed]
[17] Caberlotto, L., Lauria, M., Nguyen, T.P., et al. (2013) The Central Role of AMP-Kinase and Energy Homeostasis Impairment in Alzheimer’s Disease: A Multifactor Network Analysis. PLOS ONE, 8, e78919. [Google Scholar] [CrossRef] [PubMed]